Resultados y vida financieraSalud - Farma - Biotecnología
Amoéba announces the publication of its half-year financial report as of June 30, 2026
30/10/2026 17:00
AMFPublicación inmediata
Chassieu (France), 30 October 2026 – 6.00 pm – Amoéba (FR0011051598 - ALMIB), an industrial greentech company specialising in the development of natural microbiological solutions based on the patented use of amoebae, announces that it has made available and filed with the French Financial Markets…
Address: 38 Avenue des Frères Montgolfier, 69680 CHASSIEU
Public Limited Company with a share capital of €2,598,882.34
Lyon Trade and Companies Register No. 523 877 215
Tel: +33 (0)4 26 69 16 00 – Email: contact@amoeba-nature.com
LinkedIn: @amoeba-nature www.amoeba-nature.com
Press release
Amoéba announces the publication of its halfyear financial report as of June 30, 2026
Chassieu (France), 30 October 2026 – 6.00 pm – Amoéba (FR0011051598 - ALMIB), an industrial greentech company specialising in the development of natural microbiological solutions based on the patented use of amoebae, announces that it has made available and filed with the French Financial Markets Authority (“Autorité des marchés financiers”, AMF) its half-year financial report for the six months ended June 30, 2026.
The financial statements were approved by the Board of Directors on October 29, 2026 and were subject to a limited review by the Statutory Auditors, who expressed no qualifications or observations in their report. The figures are unchanged from the preliminary financial statements presented on September 24, 20261.
The half-year financial report for the six months ended June 30, 2026 is available on the Company's website at https://amoeba-nature.com/en/, under the following section: Investor / Financial Documents / 2026 / Half-year financial report.
About Amoéba:
Founded in 2010, Amoéba is a greentech company based in Chassieu (Lyon, France) whose ambition is to become a major player in the management of microbiological risk through the patented use of amoebae in the plant protection and cosmetics sectors.
With expertise that is unique in the world and protected by numerous patents, Amoéba is currently the only company authorised to utilise the Willaertia amoeba on an industrial scale for biocontrol and cosmetic applications. To the Company’s knowledge, it is also the only firm capable of producing this amoeba on an industrial scale in volumes suitable for commercial applications, thereby offering a viable alternative to the chemical products widely used today.
Amoéba is currently focusing on the global biocontrol market for plant protection and the cosmetics market. As the marketing of plant protection products is subject to obtaining local regulatory authorisations, the Company has undertaken the necessary regulatory procedures and submitted registration applications in Europe and the United States. As regards the active substance, it had already obtained approval in the US in 2022 and a positive, final opinion from EFSA in Europe. Registration of the AXPERA product was granted in 2025 for the United States and in 2026 in France, followed by other targeted European countries.